| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Child Health, London IDEAS Genetics Knowledge Park, UCL, 30 Guilford Street, London WC1N 1EH;
2 London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT;
3 The Royal Oldham Hospital, The Pennine Acute Hospitals NHS Trust, Rochdale Road, Oldham OL1 2JH;
4 The Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham B15 2TH;
5 Royal Bournemouth Hospital, The Royal Bournemouth and Christchurch Hospitals NHS Trust, Castle Lane East, Bournemouth BH7 7DW;
6 Royal Surrey County Hospital, Royal Surrey County Hospital NHS Trust, Egerton Road, Guildford, Surrey GU2 7XX;
7 Heart of England NHS Foundation Trust, Birmingham B9 5SS;
8 Nottingham University Hospitals NHS Trust, City Campus, Hucknall Road, Nottingham NG5 1PB;
9 Royal Albert Edward Infirmary, Wrightington, Wigan and Leigh NHS Trust, Wigan Lane, Wigan WN1 2NN;
10 Hope Hospital, Salford Royal Hospitals NHS Trust, Stott Lane, Salford M6 8HD;
11 Trafford General Hospital, Trafford Healthcare NHS Trust, Moorside Road, Davyhulme, Manchester M41 5SL;
12 Frimley Park Hospital NHS Foundation Trust, Portsmouth Road, Frimley, Surrey GU16 7UJ;
13 Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, The Rayne Building, Royal Free and University College London Medical School, London WC1E 6JJ, UK
Corresponding author: Prof S E Humphries. Email: rmhaseh{at}ucl.ac.uk
Background: Family tracing is a method recognized to find new patients with familial hypercholesterolaemia (FH). We have implemented family tracing led by FH Nurses and have determined acceptability to patients, feasibility and costs.
Methods: Nurses were located at five National Health Service (NHS) Trusts; they identified FH patients and offered them family tracing. Responses and test results were recorded on a database and summarized on a family pedigree.
Results: The majority (
70%) of index cases participated; the proportion was lower when patients had been discharged from the clinics and in metropolitan areas. On average, 34% (range 13–50%) of relatives lived outside the catchment area of the clinics and could not attend the nurse-led FH clinics. Of the previously untested relatives, 76% who lived in the catchment area of the clinic came forward to be tested. One-third of the relatives who came forward for testing were children
16 y of age. The proportion of relatives diagnosed as likely to have FH was lower than would be predicted (30% vs. 50%). This was mainly due to the uncertainty of a diagnosis based on lipid measurements. The average cost to identify and test one relative was approximately £500 but was higher in the metropolitan areas.
Conclusion: Cascade testing for FH in the UK is feasible, acceptable and likely to be cost-effective if it is a routine aspect of clinical care. However, national implementation would require an integrated infrastructure, so that all individuals have access to testing, and specialist services for the management of young people.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. I Bima, A. J Hooper, F. M van Bockxmeer, and J. R Burnett Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia Ann Clin Biochem, September 1, 2009; 46(5): 420 - 422. [Abstract] [Full Text] [PDF] |
||||